Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans
Atsuo Ochi, … , Cristina Hajdu, George Miller
Atsuo Ochi, … , Cristina Hajdu, George Miller
Published October 1, 2012
Citation Information: J Clin Invest. 2012;122(11):4118-4129. https://doi.org/10.1172/JCI63606.
View: Text | PDF
Research Article Oncology

Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma is an aggressive cancer that interacts with stromal cells to produce a highly inflammatory tumor microenvironment that promotes tumor growth and invasiveness. The precise interplay between tumor and stroma remains poorly understood. TLRs mediate interactions between environmental stimuli and innate immunity and trigger proinflammatory signaling cascades. Our finding that TLR7 expression is upregulated in both epithelial and stromal compartments in human and murine pancreatic cancer led us to postulate that carcinogenesis is dependent on TLR7 signaling. In a mouse model of pancreatic cancer, TLR7 ligation vigorously accelerated tumor progression and induced loss of expression of PTEN, p16, and cyclin D1 and upregulation of p21, p27, p53, c-Myc, SHPTP1, TGF-β, PPARγ, and cyclin B1. Furthermore, TLR7 ligation induced STAT3 activation and interfaced with Notch as well as canonical NF-κB and MAP kinase pathways, but downregulated expression of Notch target genes. Moreover, blockade of TLR7 protected against carcinogenesis. Since pancreatic tumorigenesis requires stromal expansion, we proposed that TLR7 ligation modulates pancreatic cancer by driving stromal inflammation. Accordingly, we found that mice lacking TLR7 exclusively within their inflammatory cells were protected from neoplasia. These data suggest that targeting TLR7 holds promise for treatment of human pancreatic cancer.

Authors

Atsuo Ochi, Christopher S. Graffeo, Constantinos P. Zambirinis, Adeel Rehman, Michael Hackman, Nina Fallon, Rocky M. Barilla, Justin R. Henning, Mohsin Jamal, Raghavendra Rao, Stephanie Greco, Michael Deutsch, Marco V. Medina-Zea, Usama Bin Saeed, Melvin O. Ego-Osuala, Cristina Hajdu, George Miller

×

Figure 1

High expression of TLR7 in inflammatory and epithelial cells in pancreatic carcinoma.

Options: View larger image (or click on image) Download as PowerPoint
High expression of TLR7 in inflammatory and epithelial cells in pancreat...
(A) Representative paraffin-embedded sections of pancreata from 6-month-old WT or p48Cre;KrasG12D mice. The number of TLR7+ cells per HPF was quantified (n = 6 per group). (B) Human normal (n = 5) and pancreatic cancer (n = 19) paraffin-embedded specimens were stained with mAbs directed against TLR7, and the number of TLR7+ cells per HPF was quantified. (C) Pancreatic leukocyte (CD45+) and (D) parenchymal (CD45–) cellular subsets from 6-month-old WT and p48Cre;KrasG12D mice were analyzed by flow cytometry for expression of TLR7. The percentage of cells expressing TLR7 for each cellular subset is indicated. Data are representative of experiments repeated more than 3 times. Original magnification, ×40. Scale bar: 75 μm. ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts